Objective. To assess the effectiveness of treatment of the asthenic symptom complex in patients with formed alcohol dependence (stage II alcoholism) in the post-withdrawal period using succinate-containing metabolic protectors (mexidol vs emoxypine, riboxine vs cytoflavine, metaprot vs metaprot plus). Methods. In 148 patients with formed alcohol dependence in the post-withdrawal period, clinical, psychological and instrumental methods revealed asthenic syndrome, manifested mainly by elements of anxiety and subdepressiveness, increased mental and physical fatigue, weakness, absent-mindedness, distracted attention, decreased physical and mental performance, the need for significant rest, high mental exhaustion, impaired social adaptation. Results. Metabolic protectors of a similar structure, containing (mexidol, cytoflavine, metaprot plus) or not containing (emoxipine, riboxine, metaprot) succinate in their molecule, have shown clinical efficacy in eliminating or reducing the asthenic symptom complex in this category of patients. Thus, a positive effect was noted on the scale of neurotization by L.I. Wasserman, the 7th neurotization scale of the MMPI personality questionnaire, the hospital anxiety scale, the Spielberger scale (situational anxiety), the hospital depression scale, in the SAN test (health, activity, mood), while succinate-containing drugs (mexidol, cytoflavine, metaprot plus) were more active in comparison with succinate-containing drugs (emoxipine and riboxine), the exception of the latter was metaprot, which is comparable in activity to succinate-containing drugs. Finally, of all the studied drugs, mexidol, cytoflavine, metaprot and metaprot plus significantly reduced the craving for alcohol, and the degree of decrease in craving for alcohol was 67.5-76.8%. The antiasthenic effect manifested itself as anti-asthenic, antidepressant, anti-anxiety, nootropic (cognitive) and positive general somatic action of the drugs. Conclusion. It is recommended to pay special attention to the correction of asthenic disorders and to use succinate-containing metabolic protectors in the treatment of patients with formed alcohol dependence (stage II alcoholism) in the post-withdrawal period.